Sex differences in medical cannabis-related adverse effects? Do not forget the context!
- PMID: 36383424
- DOI: 10.1097/j.pain.0000000000002771
Sex differences in medical cannabis-related adverse effects? Do not forget the context!
Comment on
-
Sex differences in medical cannabis-related adverse effects.Pain. 2022 May 1;163(5):975-983. doi: 10.1097/j.pain.0000000000002463. Pain. 2022. PMID: 34538843 Free PMC article.
References
-
- André A, Leupin M, Kneubühl M, Pedan V, Chetschik I. Evolution of the polyphenol and terpene content, antioxidant activity and plant morphology of eight different fiber-type cultivars of cannabis sativa L. Cultivated at three sowing densities. Plants Basel Switz 2020;9:E1740.
-
- Aviram J, Lewitus GM, Vysotski Y, Berman P, Shapira A, Procaccia S, Meiri D. Sex differences in medical cannabis-related adverse effects. PAIN 2022;163:975–83.
-
- Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med 2020;382:554–61.
-
- Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol 2012;30:78–87.
-
- Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–28.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
